SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis
A Bayesian network meta-analysis comparing SGLT2 inhibitors, semaglutide, and finerenone—the three therapies with contemporary phase 3 cardiorenal evidence—to define their comparative efficacy and safety hierarchy in type 2 diabetes with chronic kidney disease supports a four-pillar framework.